NMTC NEUROONE MEDICAL TECHNOLOGIES CORP

NeuroOne® to Report Fourth Quarter and Fiscal Year 2024 Financial Results on December 17 at 9:00 a.m. Eastern Time

NeuroOne® to Report Fourth Quarter and Fiscal Year 2024 Financial Results on December 17 at 9:00 a.m. Eastern Time

EDEN PRAIRIE, Minn., Dec. 04, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for the fiscal fourth quarter and year ended September 30, 2024, before market open on December 17, 2024.

Management will host an investor conference call and webcast at 9:00 a.m. Eastern time on Tuesday, December 17, 2024 to discuss the Company’s fourth quarter and fiscal year 2024 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following infomaiton:

Fourth Quarter and Fiscal 2024 Earnings Conference Call

Date: Tuesday, December 17, 2024

Time: 9:00 a.m. Eastern time

U.S. Dial-In (Toll Free): 888-506-0062

International Dial-In: 973-528-0011

Participant Access Code: 603219

Webcast:

Please join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through December 31, 2024. To listen, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 51728. A webcast replay will also be available using the webcast link above through December 17, 2025.

About NeuroOne

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit .

IR Contact

MZ Group – MZ North America



EN
04/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUROONE MEDICAL TECHNOLOGIES CORP

 PRESS RELEASE

NeuroOne Strengthens Leadership Team with Appointment of Emily Johns a...

NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, “We are excited to ...

 PRESS RELEASE

NeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference...

NeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025 EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025. Dave Rosa, President and CEO of NeuroOne will be meeting with investors during t...

 PRESS RELEASE

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; G...

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6% Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological di...

 PRESS RELEASE

NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medic...

NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch